Professor of Medicine
Department of Medicine
Division of Digestive Diseases
David Geffen School of Medicine
University of California, Los Angeles
Los Angeles, California

Lin Chang, MD, is a Professor of Medicine in the Department of Medicine, Division of Digestive Diseases, at the David Geffen School of Medicine at UCLA. She serves as the Co-Director of the Center for Neurobiology of Stress at the David Geffen School of Medicine at UCLA. This center is an interdisciplinary research and education organization, dedicated to the study of brain-body interactions in health and disease. Dr. Chang earned her medical degree from the UCLA School of Medicine and completed her internship and residency in internal medicine at Harbor-UCLA Medical Center. She completed her gastroenterology fellowship training at the UCLA Affiliated Training Program in Gastroenterology. Dr. Chang’s clinical expertise is in functional gastrointestinal disorders which include irritable bowel syndrome (IBS), chronic constipation, and functional dyspepsia. Dr. Chang’s research is focused on the pathophysiology of IBS related to stress, sex differences, and neuroendocrine alterations and the treatment of IBS. She is a funded NIH-investigator studying the central and peripheral mechanisms underlying IBS. She is the recipient of the Janssen Award in Gastroenterology for Basic or Clinical Research and the AGA Distinguished Clinician Award, Dr. Chang has authored more than 70 original research articles, 48 review articles, and 19 book chapters on her specialty interests and is a frequent speaker at national and international meetings. She is a fellow of the American Gastroenterological Association and an active member of several professional societies, including the American College of Gastroenterology and the Society for Neuroscience. She is also a member of the Rome Foundation Board of Directors and served as the Co-Chair of the Rome III Gender, Age, Cultural and Patient Perspective committee. She is the President Elect in the newly merged American Neurogastroenterology and Motility Society (ANMS). She served on the FDA GI Advisory Committee from 2005-2010 which she also chaired.

UCLA - David Geffen School of Medicine

In just over 50 years - within the lifetimes of many of its original architects - the David Geffen School of Medicine at UCLA has joined the ranks of the nations elite medical schools.

The medical school today has more than 2,000 full-time faculty members, almost 1,300 residents, more than 750 medical students and almost 400 Ph.D. candidates. The UCLA Medical Center has been ranked "Best in the West" by U.S. News and World Report's annual survey of the best hospitals in America for fourteen consecutive years. The medical school is ranked ninth in the country in research funding from the National Institutes of Health and third in the United States in research dollars from all sources.

The Ronald Reagan UCLA Medical Center, designed by I.M. Pei, opened its doors in 2008 and is a model for state-of-the-art medical science and patient care in a patient- and staff-friendly environment. The new Santa Monica-UCLA Medical Center replacement hospital, designed by prominent New York architect Robert A.M. Stern in conjunction with CO Architects, opened its doors in 2008.

In 2010, Dr. A. Eugene Washington, an internationally renowned clinical investigator and health policy scholar whose wide-ranging research has been instrumental in shaping national health policy and practice guidelines, joined UCLA Feb. 1 as Vice Chancellor of UCLA Health Sciences and Dean of the David Geffen School of Medicine.

The dream of the school's founders has been realized. The David Geffen School of Medicine is an internationally recognized leader in research, medical education, and patient care.

 52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D) (IRIS-4)

Irritable Bowel Syndrome with diarrhoea (IBS-D) is a functional gastrointestinal disorder characterised by chronic or recurrent abdominal pain or discomfort and diarrhoea. This trial aims at the evaluation of the efficacy and safety of oral ibodutant 10 mg once daily as compared to placebo in women with IBS-D over a 24-week treatment period

Estimated Enrollment: 500
Study Start Date: March 2014
Estimated Study Completion Date: April 2016
Estimated Primary Completion Date: February 2016 (Final data collection date for primary outcome measure)

Ages Eligible for Study: 18 Years and older
Genders Eligible for Study: Female
Accepts Healthy Volunteers: No